Fortress Biotech Inc (FBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $62.70M
Last updated: Nov 17, 2026 at 11:04 AM ET
Fortress Biotech Inc (FBIO) Earnings: Report Dates and Results
Fortress Biotech (FBIO) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Fortress Biotech reported EPS of -$0.23, above the -$0.27 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
FBIO has an expected report date of Mar 29, 2027.
FBIO Earnings Call
The latest FBIO earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 39 quarters below that had an estimate, FBIO beat 19, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $19.16M, up 8.7% from $17.63M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.23 | -$0.27 | -$0.27 - -$0.27 | +14.81% | Beat | -309.1% | 1 | 0 up, 1 down | Nov 13, 2026 | $19.16M |
| Jun 30, 2026 | -$0.08 | -$0.20 | -$0.20 - -$0.20 | +60.00% | Beat | N/A | 1 | 0 up, 1 down | Aug 13, 2026 | $18.72M |
| Mar 31, 2026 | $2.82 | -$0.22 | -$0.22 - -$0.22 | N/A | N/A | N/A | 1 | 0 up, 0 down | May 14, 2026 | $16.04M |
| Dec 31, 2025 | -$0.21 | $0.11 | -$0.20 - $0.42 | -290.91% | Miss | N/A | 2 | 1 up, 0 down | Mar 31, 2026 | $16.08M |
| Sep 30, 2025 | $0.11 | -$0.62 | -$0.84 - -$0.41 | +117.74% | Beat | N/A | 2 | 0 up, 1 down | Nov 14, 2025 | $17.63M |
| Jun 30, 2025 | -$0.51 | -$0.31 | -$0.31 - -$0.31 | -64.52% | Miss | N/A | 1 | 1 up, 0 down | Aug 14, 2025 | $16.41M |
| Mar 31, 2025 | -$0.48 | -$0.44 | -$0.44 - -$0.44 | -9.09% | Miss | N/A | 1 | 0 up, 0 down | May 21, 2025 | $13.14M |
| Dec 31, 2024 | -$0.30 | -$0.75 | -$0.75 - -$0.75 | +60.09% | Beat | N/A | 1 | 0 up, 1 down | Mar 27, 2025 | $15.16M |
| Sep 30, 2024 | -$0.76 | -$0.27 | -$0.92 - -$0.27 | -181.48% | Miss | N/A | 2 | 0 up, 0 down | Nov 14, 2024 | $14.63M |
| Jun 30, 2024 | -$0.73 | -$1.22 | -$1.75 - -$0.88 | +40.16% | Beat | N/A | 3 | 0 up, 0 down | Aug 13, 2024 | $14.86M |
| Mar 31, 2024 | -$1.03 | -$1.73 | -$2.60 - -$1.13 | +40.46% | Beat | N/A | 3 | 0 up, 0 down | May 15, 2024 | $13.03M |
| Dec 31, 2023 | -$1.28 | -$1.97 | -$2.61 - -$1.49 | +35.03% | Beat | N/A | 3 | 1 up, 0 down | Mar 28, 2024 | $19.95M |
| Sep 30, 2023 | -$0.94 | -$1.50 | N/A | +37.33% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2023 | $34.75M |
| Jun 30, 2023 | -$1.05 | -$0.90 | N/A | -16.67% | Miss | N/A | 4 | 0 up, 0 down | Aug 14, 2023 | $17.39M |
| Mar 31, 2023 | -$0.90 | $0.45 | N/A | -300.00% | Miss | N/A | 4 | 0 up, 0 down | May 15, 2023 | $12.43M |
| Dec 31, 2022 | -$0.30 | -$0.22 | -$0.29 - -$0.15 | -36.36% | Miss | N/A | 4 | 0 up, 0 down | Mar 30, 2023 | $16.40M |
| Sep 30, 2022 | -$1.20 | -$1.05 | N/A | -14.29% | Miss | -114.8% | 6 | 0 up, 0 down | Nov 14, 2022 | $16.53M |
| Jun 30, 2022 | -$1.50 | -$1.12 | -$4.65 - -$0.45 | -33.93% | Miss | N/A | 7 | 0 up, 0 down | Aug 11, 2022 | $18.89M |
| Mar 31, 2022 | -$1.05 | $0.15 | N/A | -800.00% | Miss | N/A | 3 | 1 up, 0 down | May 12, 2022 | $23.93M |
| Dec 31, 2021 | -$0.38 | $0.18 | -$0.14 - $0.47 | -311.11% | Miss | N/A | 5 | 0 up, 0 down | Mar 28, 2022 | $18.28M |
| Sep 30, 2021 | $8.10 | -$2.85 | N/A | +384.21% | Beat | N/A | 6 | N/A | Nov 15, 2021 | $21.09M |
| Jun 30, 2021 | -$2.55 | -$1.80 | -$3.00 - -$0.30 | -41.67% | Miss | N/A | 6 | N/A | Aug 16, 2021 | $17.84M |
| Mar 31, 2021 | -$1.35 | -$0.70 | N/A | -92.86% | Miss | N/A | 4 | N/A | May 16, 2021 | $11.59M |
| Dec 31, 2020 | -$0.05 | -$0.14 | -$0.18 - -$0.09 | +64.29% | Beat | N/A | 6 | N/A | Mar 31, 2021 | $13.75M |
| Sep 30, 2020 | -$3.02 | -$2.10 | -$7.95 - -$0.75 | -43.81% | Miss | N/A | 6 | N/A | Nov 9, 2020 | $9.47M |
| Jun 30, 2020 | -$2.84 | -$2.50 | N/A | -13.60% | Miss | N/A | 5 | N/A | Aug 10, 2020 | $9.46M |
| Mar 31, 2020 | -$2.91 | -$3.60 | -$4.05 - -$3.15 | +19.17% | Beat | -1070.0% | 4 | N/A | May 11, 2020 | $12.92M |
| Dec 31, 2019 | -$0.27 | -$0.31 | -$0.43 - -$0.26 | +12.90% | Beat | N/A | 5 | N/A | Mar 16, 2020 | $11.13M |
| Sep 30, 2019 | -$3.30 | -$5.10 | -$5.10 - -$3.90 | +35.29% | Beat | N/A | 2 | N/A | Nov 12, 2019 | $9.77M |
| Jun 30, 2019 | -$3.60 | -$6.00 | -$7.80 - -$6.00 | +40.00% | Beat | N/A | 2 | N/A | Aug 9, 2019 | $9.25M |
| Mar 31, 2019 | $0.30 | -$8.70 | -$8.70 - -$8.70 | +103.45% | Beat | N/A | 1 | N/A | May 10, 2019 | $6.48M |
| Dec 31, 2018 | -$0.58 | -$0.58 | -$0.58 - -$0.58 | 0.00% | In line | N/A | 1 | N/A | Mar 18, 2019 | $8.99M |
| Sep 30, 2018 | -$5.55 | -$8.55 | N/A | +35.09% | Beat | N/A | 1 | N/A | Nov 9, 2018 | $5.17M |
| Jun 30, 2018 | -$7.50 | -$8.80 | -$11.09 - -$6.45 | +14.77% | Beat | N/A | 3 | N/A | Aug 9, 2018 | $6.82M |
| Mar 31, 2018 | -$7.35 | -$6.00 | -$7.20 - -$5.10 | -22.50% | Miss | N/A | 3 | N/A | May 10, 2018 | $5.90M |
| Dec 31, 2017 | -$0.22 | -$0.63 | -$0.68 - -$0.57 | +65.08% | Beat | N/A | 3 | N/A | Mar 16, 2018 | $45.32M |
| Sep 30, 2017 | -$10.05 | -$6.37 | -$6.90 - -$5.85 | -57.77% | Miss | N/A | 2 | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$6.45 | -$4.42 | -$4.80 - -$4.05 | -45.93% | Miss | N/A | 2 | N/A | Aug 9, 2017 | $50.70M |
| Mar 31, 2017 | -$4.50 | -$5.40 | N/A | +16.67% | Beat | N/A | N/A | N/A | May 10, 2017 | $44.68M |
| Dec 31, 2016 | -$0.44 | -$0.31 | N/A | -41.94% | Miss | N/A | N/A | N/A | Mar 16, 2017 | $42.11M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.09, after -$2.82 the year before. It was -$10.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.09 | N/A |
| Dec 31, 2024 | -$2.82 | N/A |
| Dec 31, 2023 | -$4.17 | N/A |
| Dec 31, 2022 | -$4.05 | -206.0% |
| Dec 31, 2021 | $3.82 | N/A |
| Dec 31, 2020 | -$8.82 | N/A |
| Dec 31, 2019 | -$6.87 | N/A |
| Dec 31, 2018 | -$20.98 | N/A |
| Dec 31, 2017 | -$21.22 | N/A |
| Dec 31, 2016 | -$10.20 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,200 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,161 | 9 | |
| 2025Q3 | Sep 30, 2025 | 4,896 | 9 |
2026Q2 Earnings Call
Opening remarks
Jaclyn Jaffe Senior Director of Corporate Operations Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; Joseph Benesch, Chief Financial Officer; and Ramsey Alloush, Chief Operating Officer and General Counsel, who will participate in the Q&A portion of the call. During this call, management will be making forward-looking statements, including statements that address among other things, Journey Medical's expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q. The Form 8-K filed with the SEC today and the company's press release that accompanies this call, particularly the cautionary statements in it. Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time-sensitive information that is accurate only as of today, Wednesday, August 12, 2026. Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.
Claude Maraoui Co-Founder, President and Chief Executive Officer Thank you, Jaclyn, and good afternoon to everyone on the call today. We continue to make solid progress in our business in the second quarter as we delivered strong revenue growth and improved profitability during the period. Emrosi revenues were $8.1 million in Q2, up significantly year-over-year and sequentially from the first quarter on higher prescription volume, improving payer reimbursement and a significant step-up in the number of dermatology writers prescribing the brand. These metrics not only trended positively, but also showed acceleration, and we expect this progress to continue in the coming quarters. Our total net product revenues for the second quarter rose by 23% year-over-year, while operating expenses increased by less than 1% compared to Q2 of last year. We remain focused on delivering strong top line growth and leveraging our proven dermatology commercial infrastructure. We are executing on these initiatives and as a result, we generated positive EBITDA in the second quarter.
Frequently Asked Questions About FBIO
When is Fortress Biotech's next earnings date?
Fortress Biotech's next earnings report is expected for Mar 29, 2027.
Did FBIO beat earnings estimates last quarter?
Yes. Fortress Biotech reported EPS of -$0.23 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 14.81% surprise.
What EPS do analysts expect from FBIO next quarter?
The consensus EPS estimate for Fortress Biotech for the quarter ending Dec 31, 2026 is -$0.26 from 3 analysts.
How often does FBIO beat earnings estimates?
Fortress Biotech beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -36.67%.
FBIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors